Literature DB >> 9106621

Molecular cloning and expression of a 2-arylpropionyl-coenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen.

C Reichel1, R Brugger, H Bang, G Geisslinger, K Brune.   

Abstract

The 2-arylpropionic acid derivatives, including ibuprofen, are the most widely used anti-inflammatory analgesic cyclooxygenase inhibitors. The (-)-R-enantiomer, which is inactive in terms of cyclooxygenase inhibition, is epimerized in vivo via the 2-arylpropionyl-coenzyme A (CoA) epimerase to the cyclooxygenase-inhibiting (+)-S-enantiomer. The molecular biology of the epimerization pathway is largely unknown. To clarify this mechanism, the sequence of the 2-arylpropionyl-CoA epimerase was identified, and the enzyme cloned and expressed. A cDNA clone encoding the 2-arylpropionyl-CoA epimerase was isolated from a rat liver cDNA library. The nucleotide and the deduced amino acid sequence of this enzyme was determined. Significant amino acid sequence similarity was found between the rat epimerase and carnitine dehydratases from Caenorhabditis elegans (41%) and Escherichia coli (27%). A bacterial expression system (E. coli strain M15[pREP4]) was used to express the epimerase protein, representing up to 20-30% of the total cellular E. coli protein. The expression of the epimerase was confirmed with Western blots using specific anti-epimerase antibodies and by measuring the rate of inversion of (R)-ibuprofenoyl-CoA. Northern blot analysis revealed a prominent 1.9-kb mRNA transcript in different rat tissues. In addition to its obvious importance in drug metabolism, the homology of the epimerase with carnitine dehydratases from several species suggests that this protein, which up to now has only been characterized as having a role in drug transformation, has a function in lipid metabolism.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106621     DOI: 10.1124/mol.51.4.576

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  9 in total

1.  The effect of operational stressors on ibuprofen pharmacokinetics.

Authors:  Cathy Boscarino; Andrea N Edginton; Henry Peng; K Wayne Riggs; András Szeitz; Bob Cheung
Journal:  Eur J Clin Pharmacol       Date:  2012-05-31       Impact factor: 2.953

2.  Molecular cloning of cDNA species for rat and mouse liver alpha-methylacyl-CoA racemases.

Authors:  W Schmitz; H M Helander; J K Hiltunen; E Conzelmann
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

3.  Separation of Betti Reaction Product Enantiomers: Absolute Configuration and Inhibition of Botulinum Neurotoxin A.

Authors:  John H Cardellina; Rebecca C Vieira; Vanessa Eccard; Janet Skerry; Vicki Montgomery; Yvette Campbell; Virginia Roxas-Duncan; William Leister; Christopher A Leclair; David J Maloney; Daniele Padula; Gennaro Pescitelli; Ilja Khavrutskii; Xin Hu; Anders Wallqvist; Leonard A Smith
Journal:  ACS Med Chem Lett       Date:  2011-03-10       Impact factor: 4.345

Review 4.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 5.  Biochemistry and genetics of inherited disorders of peroxisomal fatty acid metabolism.

Authors:  Paul P Van Veldhoven
Journal:  J Lipid Res       Date:  2010-06-17       Impact factor: 5.922

6.  Chiral separation of ibuprofen and chiral pharmacokinetics in healthy Chinese volunteers.

Authors:  Chaonan Zheng; Haiping Hao; Guangji Wang; Guowei Sang; Jianguo Sun; Peng Li; Jing Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2008 Jan-Mar       Impact factor: 2.441

7.  Can p503s, p504s and p510s gene expression in peripheral-blood be useful as a marker of prostatic cancer?

Authors:  Maria Rosaria Cardillo; Vincenzo Gentile; Antonio Ceccariello; Laura Giacomelli; Stefano Messinetti; Franco Di Silverio
Journal:  BMC Cancer       Date:  2005-09-05       Impact factor: 4.430

8.  Syntheses and cytotoxicity of phosphatidylcholines containing ibuprofen or naproxen moieties.

Authors:  Marek Kłobucki; Anna Urbaniak; Aleksandra Grudniewska; Bartłomiej Kocbach; Gabriela Maciejewska; Grzegorz Kiełbowicz; Maciej Ugorski; Czesław Wawrzeńczyk
Journal:  Sci Rep       Date:  2019-01-18       Impact factor: 4.379

9.  From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease.

Authors:  Claudia Albertini; Marina Naldi; Sabrina Petralla; Silvia Strocchi; Daniela Grifoni; Barbara Monti; Manuela Bartolini; Maria Laura Bolognesi
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.